LB Pharmaceuticals updates prospectus with Phase 3 timing

Accepted by SEC EDGAR 07/22/2026 - 08:51 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

LB Pharmaceuticals Inc. filed a prospectus supplement to its Form S-1, updating the existing prospectus by incorporating information from a new Current Report on Form 8-K. The update centers on a press release announcing accelerated timing of topline results from the Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia. The press release, dated July 22, 2026, is incorporated by reference except for its quoted statements. The company’s common stock trades on The Nasdaq Global Market under the symbol LBRX, and the last reported sale price was $32.31 per share on July 21, 2026.

Filing Explained

The July 22 424B3 is an update to an existing S-1 prospectus, not evidence in this filing that securities were offered or sold; it adds the 8-K’s trial-results timing disclosure, with no financing amount, proceeds, issuance, or dilution established.

Key Figures

Last reported stock price: $32.31 per share Date of Form 8-K event: July 22, 2026 Exhibit number – press release: 99.1 +1 more

4 metrics

Last reported stock price $32.31 per share Common stock on The Nasdaq Global Market as of July 21, 2026

Date of Form 8-K event July 22, 2026 Date of report and press release on accelerated Phase 3 NOVA-2 topline timing

Exhibit number – press release 99.1 Press Release dated July 22, 2026 attached to Form 8-K

Inline XBRL cover exhibit 104 Cover Page Interactive Data File embedded within Inline XBRL document

Key Terms

prospectus supplement, incorporated herein by reference, topline results, Phase 3 NOVA-2 clinical trial, +1 more

5 terms

prospectus supplement regulatory

"This prospectus supplement updates, amends and supplements the prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

incorporated herein by reference regulatory

"the press release is attached as Exhibit 99.1 ... and is incorporated herein by reference"

topline results medical

"announcing accelerated timing of topline results from the Phase 3 NOVA-2 clinical trial"

Topline results are the initial, high-level summary of the most important outcomes from an event such as a clinical trial or a company reporting period — for a drug study this means whether the main goals were met and basic safety info, and for a company it often means headline revenue and profit figures. Investors care because these summaries act like a headline that quickly signals whether prospects have improved or worsened, often driving immediate market reactions before the full details are released.

Phase 3 NOVA-2 clinical trial medical

"topline results from the Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia"

Emerging growth company regulatory

"Emerging growth company   On July 22, 2026, LB Pharmaceuticals Inc"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does LB Pharmaceuticals (LBRX) disclose in this 424B3 supplement?

LB Pharmaceuticals updates its S-1 prospectus by incorporating a Form 8-K that includes a press release about accelerated timing of topline Phase 3 NOVA-2 results for LB-102 in schizophrenia.

What key clinical update does LB Pharmaceuticals (LBRX) report?

The company reports accelerated timing of topline results from its Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia, as described in a press release attached as Exhibit 99.1 to the Form 8-K.

How is the Form 8-K used in LB Pharmaceuticals’ (LBRX) prospectus?

Information from the July 22, 2026 Form 8-K, including the press release on LB-102 Phase 3 NOVA-2 topline timing, is incorporated by reference into the existing S-1 prospectus via this supplement.

On which exchange is LB Pharmaceuticals (LBRX) common stock listed?

LB Pharmaceuticals’ common stock is listed on The Nasdaq Global Market under the trading symbol LBRX, as stated in the securities registration section of the disclosure.

What was the recent trading price of LB Pharmaceuticals (LBRX) stock?

The last reported sale price of LB Pharmaceuticals’ common stock was $32.31 per share on July 21, 2026, providing a recent market reference for investors reviewing the prospectus supplement.

What risk guidance does LB Pharmaceuticals (LBRX) give investors here?

The company states that investing in its securities involves a high degree of risk and directs investors to review the “Risk Factors” section beginning on page 8 of the prospectus and any amendments or supplements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Filed pursuant to Rule 424(b)(3)
Registration No. 333-294900

PROSPECTUS SUPPLEMENT

(To the Prospectus Dated April 14, 2026)

This prospectus supplement updates, amends and supplements the prospectus dated April 14, 2026 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-294900). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the prospectus.

This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 22, 2026, which is set forth below.

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

Our common stock is listed on The Nasdaq Global Market under the symbol “LBRX.” On July 21, 2026, the last reported sale price of our common stock was $32.31 per share.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 8 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.

Neither the Securities and Exchange Commission nor any other state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is July 22, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 22, 2026

LB Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

Delaware		001-42831		81-1854347
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

One Pennsylvania Plaza, Suite 1025 New York, NY		10119
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 605-0300

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		LBRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 22, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing accelerated timing of topline results from the Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and, other than the quotes contained therein, is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated July 22, 2026.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LB PHARMACEUTICALS INC
By:		/s/ Heather Turner
		Heather Turner Chief Executive Officer

Dated: July 22, 2026